• Cart


James F. Benenati, MD, FSIRJames F. Benenati, MD, FSIR
Chief Medical Officer, Penumbra

Pulmonary embolism (PE) treatment has undergone a remarkable evolution. Advances in catheter-based therapies have expanded the options for patients with intermediate- and high-risk PE, offering the potential for rapid thrombus removal and hemodynamic improvement.

Yet despite growing adoption of these technologies, randomized evidence demonstrating their impact on patient outcomes has remained limited. That evidence base is now beginning to emerge, expanding the discussion to include patient-centered outcomes and functional measures.

Pulmonary embolism research has traditionally focused on acute outcomes: survival, hemodynamic stabilization, right ventricular recovery, and freedom from major adverse events. The recent STORM-PE randomized controlled trial adds important evidence to that foundation, demonstrating superior reduction in right heart strain with computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation compared with anticoagulation alone in patients with intermediate-high risk PE.*

Beyond its primary endpoint, STORM-PE provides insight into several additional clinical and functional outcome measures. In addition to the primary endpoint of superior improvement in RV/LV ratio, patients treated with CAVT demonstrated greater thrombus burden reduction, lower heart rates, reduced oxygen requirements, and a lower NEWS2 risk of clinical deterioration at 48 hours.

Notably, these early physiologic improvements were associated with differences in functional outcomes at 90 days. CAVT-treated patients returned to a PVFS distribution comparable to their self-reported pre-PE functional status at 90 days, whereas patients receiving anticoagulation alone did not recover to their pre-PE baseline. At 90 days CAVT-treated patients also walked significantly farther on the 6-minute walk test (479m vs 368m, P=0.003). By three months, patients in the CAVT arm achieved 94.0% of their predicted walking distance compared with 75.2% among those treated with anticoagulation alone.

These findings highlight an important evolution in how we think about success in PE care. Acute endpoints remain critical, but recovery from PE often extends well beyond hospital discharge. The field must examine whether improvements in acute physiology translate into durable functional recovery.

The next phase of PE research should focus not only on clinical and imaging endpoints, but also on understanding patient-centered outcomes. STORM-PE is notable for reporting both acute physiologic outcomes and functional outcome measures assessed at 90 days. Importantly, STORM-PE is not alone; more PE trials are incorporating functional status and other measures alongside traditional clinical endpoints.

The challenge for physicians is no longer simply helping patients survive the acute event, but supporting functional recovery following PE. The evidence base must evolve accordingly.

Important Safety Information

Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/products/peripheral-thrombectomy-cavt/. The clinical results presented herein are for informational purposes only and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors. Caution: Federal (USA) law restrictions these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. For the complete Penumbra IFU Risk Summary Statements, visit: peninc.info/risk. Please contact your local Penumbra representative for more information.

*STORM-PE was not powered to detect differences in safety.

References:

  1. Lookstein R, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: primary outcomes from the STORM-PE trial. CIRCULATION. 2025; [Published online ahead of print]. doi:10.1161/CIRCULATIONAHA.125.077232.
  2. Presented by Rosovsky, R. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk PE: primary outcome, functional endpoints, and core lab findings from STORM-PE. Presented at: VIVA (Vascular InterVentional Advances) 2025; November 3, 2025; Las Vegas, NV, USA
  3. Presented by Lookstein R, on behalf of the STORM-PE Investigators. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: 90-day functional outcomes from the STORM-PE trial. Presented at: Society of Interventional Radiology Annual Scientific Meeting; April 13, 2026; Vancouver, British Columbia, Canada.
AVF 2027 - Harmony in Venous Care February 27 - March 2 Grand Hyatt Nashville